ABT-510
Also known as: ABT-510, ABT‑510, thrombospondin mimetic, Thrombospondin‑1 mimetic peptide, TSP-1 mimetic peptide
Source ABT-510 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
ABT‑510 is a synthetic 9‑amino‑acid peptide that acts as an anti‑angiogenic agent by engaging the CD36 receptor, investigated in phase II oncology trials.
Mechanism of Action
Mimics the type I repeat of thrombospondin‑1 and binds CD36 on endothelial cells, suppressing VEGF‑driven angiogenesis
Routes of Administration
Goals & Uses
- Solid tumor treatmentOncologyLow
- solid tumor cancer therapyOncologyModerate
- anti‑angiogenic cancer therapyOncologyModerate
- Tumor angiogenesis inhibitionOncology / AntiangiogenicModerate
- ocular neovascular diseaseOphthalmologyLow
- Combination antiangiogenic therapyOncology / CombinationLow
Contraindications
- known hypersensitivity to peptideImmunologicModerate
- Known hypersensitivity to ABT-510 or peptide excipientsAllergyHigh
- hypersensitivity to peptide componentsAllergyModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
Adverse Effects
- HypertensionCardiovascularUncommonHigh blood pressure
- Injection site reactionsLocalCommon
- Injection site painLocalCommonPain at the injection site
- ThrombocytopeniaHematologicUncommonLow platelet count
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- Cytotoxic chemotherapy agentsModerate
- none identifiedLow
- Anticoagulants / antiplatelet agentsModerate
- other anti‑angiogenic agents (e.g., bevacizumab)Moderate
Population Constraints
- Severe hepatic or renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveAbsolute
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionInvestigationalUnder clinical investigation; not authorized
- United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval
- United KingdomInvestigationalNo marketing authorization
Not approved by FDA or EMA; studied in Phase II trials for melanoma, renal cell carcinoma, and sarcoma.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is ABT-510?
ABT‑510 is a synthetic 9‑amino‑acid peptide that acts as an anti‑angiogenic agent by engaging the CD36 receptor, investigated in phase II oncology trials.
What is ABT-510 used for?
ABT-510 is educationally associated with: Solid tumor treatment, solid tumor cancer therapy, anti‑angiogenic cancer therapy, Tumor angiogenesis inhibition, ocular neovascular disease, Combination antiangiogenic therapy. Educational only — not medical advice.
How is ABT-510 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of ABT-510?
Reported adverse effects include: Hypertension, Injection site reactions, Injection site pain, Thrombocytopenia, Nausea, Fatigue, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid ABT-510?
Recorded contraindications: known hypersensitivity to peptide, Known hypersensitivity to ABT-510 or peptide excipients, hypersensitivity to peptide components, Pregnancy. Consult a qualified clinician before use.